GCP
MIRM icon

GSA Capital Partners’s Mirum Pharmaceuticals MIRM Stock Holding History

GSA Capital Partners’s Portfolio MIRM Stock Details MIRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-8,251
Closed -$605K – 1932
2025
Q3 		$605K Sell
8,251
-18,800
-69% -$1.2M 0.05% 725
2025
Q2 		$1.38M Sell
27,051
-13,408
-33% -$597K 0.1% 273
2025
Q1 		$1.82M Sell
40,459
-13,664
-25% -$644K 0.16% 89
2024
Q4 		$2.24M Sell
54,123
-3,862
-7% -$161K 0.17% 63
2024
Q3 		$2.26M Buy
57,985
+51,482
+792% +$2.05M 0.17% 88
2024
Q2 		$222K Buy
+6,503
New +$170K 0.02% 1423
2022
Q2 		– Sell
-14,869
Closed -$327K – 1649
2022
Q1 		$327K Sell
14,869
-8,232
-36% -$168K 0.04% 833
2021
Q4 		$368K Sell
23,101
-16,607
-42% -$258K 0.05% 799
2021
Q3 		$791K Buy
39,708
+8,193
+26% +$133K 0.08% 429
2021
Q2 		$545K Sell
31,515
-3,344
-10% -$59.9K 0.06% 569
2021
Q1 		$691K Buy
34,859
+13,150
+61% +$252K 0.11% 212
2020
Q4 		$379K Buy
+21,709
New +$427K 0.06% 608

Other funds holding MIRM

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

GSA Capital Partners's MIRM Position: Q4 2025 in Review

GSA Capital Partners sold out of Mirum Pharmaceuticals (MIRM) in Q4 2025, closing a stake of 8,251 shares — an estimated $605K sold.

GSA Capital Partners first reported a position in MIRM in Q4 2020 and held it in 12 quarters. The position peaked at $2.26M in Q3 2024. 282 funds tracked by Wall St. Rank hold MIRM as of Q4 2025.

  • GSA Capital Partners reported no remaining Mirum Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • GSA Capital Partners sold 8,251 Mirum Pharmaceuticals shares in Q4 2025, an estimated $605K.
  • GSA Capital Partners first reported a position in Mirum Pharmaceuticals in Q4 2020 and held it in 12 quarters.
  • GSA Capital Partners's Mirum Pharmaceuticals position peaked at $2.26M in Q3 2024.
  • 282 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q4 2025.

Based on GSA Capital Partners's 13F filing for Q4 2025, filed 6 Feb 2026.